Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA. Dear Members of the SMA community, This past December marked one year since the FDA approval of SPINRAZA® (nusinersen), the first…
Today the government of Norway agreed to fund Spinraza (nusinersen) treatment for all patients with SMA under 18 years.
Today members of TreatSMA and their children attended a Fast Track Treatment Campaign meeting organised by Muscular Dystrophy UK at the House of Commons.
The National Institute for Health and Care Excellence (NICE) announced that it will appraise Spinraza as a treatment for all those with spinal muscular atrophy
On 2 January 2018 all mailboxes of TreatSMA were suspended by Google without warning. As a result, the TreatSMA team lost access to all emails, address books and shared documents which until then were hosted on Google’s G Suite service.